Table 2.
Baseline demographics: maintenance period (UNCOVER‐1 and UNCOVER‐2)
| Characteristic | IXEQ2W/PBO N = 211 | IXEQ2W/IXEQ4W N = 221 | IXEQ4W/PBO N = 191 | IXEQ4W/IXEQ4W N = 195 |
|---|---|---|---|---|
| Age mean (SD), years | 44.5 (12.6) | 43.5 (13.0) | 44.0 (13.2) | 44.1 (13.2) |
| Male, n (%) | 140 (66.4) | 151 (68.3) | 124 (64.9) | 136 (69.7) |
| Race, n (%)a | ||||
| Asian | 8 (3.8) | 8 (3.6) | 9 (4.7) | 9 (4.6) |
| Black or African American | 3 (1.4) | 3 (1.4) | 7 (3.7) | 2 (1.0) |
| White | 198 (93.8) | 208 (94.1) | 172 (90.5) | 184 (94.4) |
| Other or multiple | 2 (0.9) | 2 (0.9) | 2 (1.0) | 0 |
| BMI mean, kg/m2 (SD)a | 30.1 (6.1) | 30.2 (7.0) | 30.1 (6.8) | 30.1 (6.5) |
| Duration of psoriasis symptoms mean, years (SD) | 19.7 (12.2) | 18.4 (12.1) | 18.4 (10.7) | 20.4 (13.1) |
| BSA involved, % (SD) | 26.7 (17.6) | 27.1 (16.5) | 26.0 (15.2) | 25.8 (14.8) |
| Itch NRS score, mean (SD)b | 6.8 (2.5) | 6.5 (2.6) | 6.8 (2.6) | 6.6 (2.7) |
| PASI score, mean (SD) | 19.8 (7.9) | 19.4 (7.3) | 19.4 (6.2) | 19.3 (6.8) |
| sPGA score, mean (SD) | 3.5 (0.6) | 3.5 (0.6) | 3.5 (0.6) | 3.6 (0.6) |
BSA, body surface area; BMI, body mass index; IXEQ2W, ixekizumab 80 mg every 2 weeks; IXEQ4W, ixekizumab 80 mg every 4 weeks; N, population size; n, number in group; NRS, Numeric Rating Scale; PASI, Psoriasis Area and Severity Index; PBO, placebo, sPGA, static Physician's Global Assessment; SD, standard deviation.
a
n = 190 for IXEQ4W/PBO.
b
n = 193 for IXEQ4W/IXEQ4W.